Immunitybio Stock Performance
| IBRX Stock | USD 3.47 0.31 9.81% |
The company retains a Market Volatility (i.e., Beta) of 1.98, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunitybio will likely underperform. At this point, Immunitybio has a negative expected return of -0.4%. Please make sure to check out Immunitybio's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immunitybio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunitybio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 105 M |
Immunitybio |
Immunitybio Relative Risk vs. Return Landscape
If you would invest 520.00 in Immunitybio on November 2, 2024 and sell it today you would lose (173.00) from holding Immunitybio or give up 33.27% of portfolio value over 90 days. Immunitybio is currently does not generate positive expected returns and assumes 7.2712% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Immunitybio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunitybio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunitybio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunitybio, and traders can use it to determine the average amount a Immunitybio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0548
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IBRX |
Estimated Market Risk
| 7.27 actual daily | 64 64% of assets are less volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunitybio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunitybio by adding Immunitybio to a well-diversified portfolio.
Immunitybio Fundamentals Growth
Immunitybio Stock prices reflect investors' perceptions of the future prospects and financial health of Immunitybio, and Immunitybio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunitybio Stock performance.
| Return On Asset | -0.56 | ||||
| Operating Margin | (13.14) % | ||||
| Current Valuation | 3.15 B | ||||
| Shares Outstanding | 730.16 M | ||||
| Price To Sales | 345.56 X | ||||
| Revenue | 622 K | ||||
| EBITDA | (436.18 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 726.72 M | ||||
| Book Value Per Share | (1.07) X | ||||
| Cash Flow From Operations | (366.76 M) | ||||
| Earnings Per Share | (0.90) X | ||||
| Total Asset | 504.45 M | ||||
| Retained Earnings | (2.96 B) | ||||
About Immunitybio Performance
Evaluating Immunitybio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunitybio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunitybio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people.Things to note about Immunitybio performance evaluation
Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunitybio generated a negative expected return over the last 90 days | |
| Immunitybio has high historical volatility and very poor performance | |
| Immunitybio has a very high chance of going through financial distress in the upcoming years | |
| Immunitybio currently holds 726.72 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 7.33 M. | |
| Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Roughly 74.0% of the company shares are held by company insiders |
- Analyzing Immunitybio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunitybio's stock is overvalued or undervalued compared to its peers.
- Examining Immunitybio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunitybio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunitybio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunitybio's stock. These opinions can provide insight into Immunitybio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.